The enhanced hypercalcemic response to 20-epi-1,25-dihydroxyvitamin D3 results from a selective and prolonged induction of intestinal calcium-regulating genes.
20-Epi-1,25-dihydroxyvitamin D(3) (20-epi-1,25(OH)(2)D(3)) is a vitamin D analog that exhibits unique biologic properties. The mechanism(s) responsible for these activities remains unclear. Here we explore the ability of 20-epi-1,25(OH)(2)D(3) to induce calcemic responses in mice in vivo and identify a potential mechanism. Surprisingly, the levels of calcemia induced at 24 h after single injections of equivalent doses of 1,25(OH)(2)D(3) or 20-epi-1,25(OH)(2)D(3) were similar, suggesting that both compounds were equal in both potency and efficacy. This similarity was also observed at genes involved in calcium homeostasis including, S100g (calbindin D9K), Trpv6, Cldn2 (claudin 2), Trpv5, and Tnfsf11 (Rankl) as well as Cyp24a1. Despite this, the activities of the two compounds at 48 h were strikingly different. Thus, whereas the activity of 1,25-dihydroxyvitamin D(3) declined at this time point, the response to 20-epi-1,25(OH)(2)D(3) was increased. This unique profile was not due to an exaggerated induction of calcium regulating genes in the intestine, kidney, or bone but to a sustained action on these genes in the intestine. This conclusion was supported by studies using in vivo chromatin immunoprecipitation analysis, which revealed a prolonged presence of vitamin D receptor and RNA polymerase II at the Trpv6 and Cyp24a1 promoters and a sustained increase in histone 4 acetylation in these gene regions as well. We conclude that 20-epi-1,25(OH)(2)D(3) displays superagonist properties largely as a result of its duration of action in the intestine. This action is likely due to a decrease in the rate of intestinal-specific degradation of the ligand rather than to an increase in the functional stability of the vitamin D receptor.
Department of Biochemistry, University of Wisconsin at Madison, Madison, Wisconsin 53706, USA.
Lee A
LA
Zella
Mark B
MB
Meyer
Robert D
RD
Nerenz
J Wesley
JW
Pike
D000107:Acetylation / Q000187:drug effects; D000818:Animals; D002117:Calcitriol / Q000494:pharmacology*; D002118:Calcium / Q000097:blood* / Q000378:metabolism; D002120:Calcium Channel Agonists / Q000494:pharmacology*; D015220:Calcium Channels / Q000235:genetics; D002460:Cell Line; D047369:Chromatin Immunoprecipitation; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D006657:Histones / Q000378:metabolism; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism*; D007422:Intestines / Q000166:cytology / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D012319:RNA Polymerase II / Q000378:metabolism; D051381:Rats; D018167:Receptors, Calcitriol / Q000378:metabolism; D013250:Steroid Hydroxylases / Q000235:genetics; D050916:TRPV Cation Channels / Q000235:genetics; D014162:Transfection; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000494:pharmacology; D065668:Vitamin D3 24-Hydroxylase
D002120:Calcium Channel Agonists; D015220:Calcium Channels; D006657:Histones; D018167:Receptors, Calcitriol; D050916:TRPV Cation Channels; C422827:TRPV6 protein, human; D014807:Vitamin D; C097949:1,25-dihydroxyvitamin D; D013250:Steroid Hydroxylases; C585549:CYP24A1 protein, human; C585550:Cyp24a1 protein, mouse; C585551:Cyp24a1 protein, rat; D065668:Vitamin D3 24-Hydroxylase; D012319:RNA Polymerase II; D002117:Calcitriol; D002118:Calcium